NEWSAR
Multi-perspective news intelligence
SRCSouth China Morning Post
LANGEN
LEANCenter-Right
WORDS141
ENT9
THU · 2026-09-24 · 06:29 GMTBRIEF NSR-2026-0924-113692
News/Chinese drug loberamisal extends stroke treatment window fro…
NSR-2026-0924-113692News Report·EN·Public Health

Chinese drug loberamisal extends stroke treatment window from 6 hours to 2 days

Chinese medical scientists have developed a new drug, loberamisal, that significantly extends the treatment window for stroke patients. Previously, emergency stroke treatments were limited to within six hours of symptom onset.

Shi HuangSouth China Morning PostFiled 2026-09-24 · 06:29 GMTLean · Center-RightRead · 1 min
Chinese drug loberamisal extends stroke treatment window from 6 hours to 2 days
South China Morning PostFIG 01
Reading time
1min
Word count
141words
Sources cited
1cited
Entities identified
9entities
Quality score
100%
§ 01

Briefing Summary

AI-generated
NEWSAR · AI

Chinese medical scientists have developed a new drug, loberamisal, that significantly extends the treatment window for stroke patients. Previously, emergency stroke treatments were limited to within six hours of symptom onset. Clinical trials published in the Journal of the American Medical Association demonstrated that loberamisal, administered intravenously, allows for effective treatment up to 48 hours after a stroke. This expansion of the treatment window dramatically improves patient outcomes. In a large-scale trial, 70% of patients receiving loberamisal within two days of a stroke regained complete functional independence, a 13 percentage point increase compared to standard care. This breakthrough offers hope for more stroke patients to achieve full recovery.

Confidence 0.85Sources 1Claims 4Entities 9
§ 02

Article analysis

Model · rule-based
Framing
Public Health
Technology
Tone
Mixed Tone
AI-assessed
CalmNeutralAlarmist
Factuality
0.90 / 1.00
Factual
LowHigh
Sources cited
1
Limited
FewMany
§ 03

Key claims

4 extracted
01

This represents a 13 percentage point increase in complete functional independence compared to standard care alone.

statisticLarge-scale multicentre phase 3 trial
Confidence
1.00
02

70% of patients who received loberamisal intravenously within two days of a stroke regained complete functional independence.

statisticLarge-scale multicentre phase 3 trial
Confidence
1.00
03

Clinical trials of loberamisal found it was possible to expand the time available for stroke treatment to 48 hours.

factualJournal of the American Medical Association study
Confidence
1.00
04

Chinese medical scientists have developed a drug, loberamisal, that extends the stroke treatment window from 6 hours to 48 hours.

factualChinese medical scientists
Confidence
1.00
§ 04

Full report

1 min read · 141 words
Chinese medical scientists have shattered the brief window of time available to limit stroke damage, effectively shielding injured brain cells and dramatically improving the odds of a full recovery.brain cells start dying within minutes of a clot blocking an artery, leading to facial droop, affected speech and in severe cases, paralysis or death. Emergency treatments, such as clot-busting drugs or surgery, must be given within a maximum of six hours.According to a study published by the top-tier Journal of the American Medical Association on September 10, clinical trials of the drug loberamisal found it was possible to expand the time available to 48 hours.The large-scale multicentre phase 3 trial found that 70 per cent of patients who received loberamisal intravenously within two days of a stroke regained complete functional independence – an increase of 13 percentage points over standard care alone.
§ 05

Entities

9 identified
§ 06

Keywords & salience

9 terms
loberamisal
1.00
stroke treatment
1.00
brain cells
0.80
treatment window
0.80
functional independence
0.70
clot-busting drugs
0.60
medical scientists
0.50
clinical trials
0.50
journal of the american medical association
0.40
§ 07

Topic connections

Interactive graph